05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
Dietary supplements for human beings; dietary supplements
for pets; dietary supplements for infants; dietary
supplements and dietetic preparations; food supplements in
liquid form. Oils for food; cooking oils.
3.
PHOSPHOLIPID COMPOSITIONS FOR DELIVERY OF THERAPEUTIC COMPOUNDS
The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, CoQ10 and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
(1) Dietary supplements for human beings; dietary supplements for pets; dietary supplements for infants; dietary supplements and dietetic preparations; food supplements in liquid form.
(2) Oils for food; cooking oils.
29 - Meat, dairy products, prepared or preserved foods
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Oils for food; cooking oils. Dietary supplements for human beings; dietary supplements for pets; dietary supplements for infants; dietary supplements and dietetic preparations; food supplements in liquid form.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary and nutritional supplements containing fish oil and extracts from marine organisms; dietary and nutritional supplements containing ingredients, namely, fish oil, krill oil, made in significant part of krill; dietary supplements for human consumption containing krill oil or other krill derivatives, namely, krill meal; food supplements containing krill.
This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extracts the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to compositions comprising phospholipids for delivery of bioactive compounds such as ethyl esters, fish oil concentrates, cannabinoids, CoQ10 and curcumin under conditions such the bioavailability of the bioactive compounds is enhanced.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
A23K 20/179 - Colouring agents, e.g. pigmenting or dyeing agents
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
The present invention relates to pharmaceutical formulations of phospholipids, and in particular pharmaceutical formulations which are administered intravascularly such as intravenously. In particular, the present invention provides pharmaceutical compositions for intravascular administration comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
It is provided processes for generating a therapeutic concentrated phospholipid composition from raw krill oil containing high content of free fatty acids. Particularly it is provided a process producing a concentrated phospholipid composition comprising the steps of: fractionating a raw hill oil (RKO) containing at least 7% of free fatty acids (FFA) obtaining a fraction enriched in phospholipids and an undesired layer; and separating said fraction enriched in phospholipids from the undesired layer, producing the therapeutic concentrated phospholipid composition with a yield of at least 30%.
C11C 3/06 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis by esterification of fats or fatty oils with glycerol
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
The present invention provides marine lysophosphatidylcholine compositions for use in pharmaceuticals, nutraceuticals and functional foods, as well as methods for making marine lysophosphatidylcholine compositions.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A23D 9/00 - Other edible oils or fats, e.g. shortenings or cooking oils
A23J 7/00 - Phosphatide compositions for foodstuffs, e.g. lecithin
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
AKER BIOMARINE HUMAN INGREDIENTS AS (Norway)
Inventor
Myhren, Finn
Hals, Petter-Arnt
Hoem, Nils
Storsve, Andreas Berg
Subbaiah, Papasani V.
Yalagala, Poorna
Dhavamani, Sugasini
Tai, Leon
Abstract
The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
An apparatus for metering and dispensing a predetermined amount of a viscous substance includes an inlet fluidly connected to a supply flow path that branches into a metering flow path and a first dispensing flow path which branches into a second dispensing flow path that is angled relative to the first dispensing flow path. The apparatus also includes a supply valve disposed in the supply flow path, a dispensing valve disposed in the first dispensing flow path and the second dispensing flow path, a metering piston disposed in the metering flow path, and a dispensing piston. A method of metering and dispensing a volume of a viscous substance is also provided.
G01F 13/00 - Apparatus for measuring by volume and delivering fluids or fluent solid materials, not provided for in the preceding groups
G01F 11/02 - Apparatus requiring external operation adapted at each repeated and identical operation to measure and separate a predetermined volume of fluid or fluent solid material from a supply or container, without regard to weight, and to deliver it with measuring chambers which expand or contract during measurement
A23P 10/30 - Encapsulation of particles, e.g. foodstuff additives
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
Fatty acids for industrial purposes; lecithin for industrial
purposes. Nutritional supplements; pharmaceuticals; dietary and
nutritional supplements; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; dietetic substances adapted for medical use;
cardiovascular pharmaceuticals; pharmaceutical drugs; eye
drops; ophthalmic preparations; pharmaceutical preparations
for the treatment of eye diseases and conditions; food for
babies; infant formula; nasal sprays for medical purposes;
decongestant nasal sprays; nasal spray preparations. Edible oils.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
(1) Fatty acids for industrial purposes.
(2) Nutritional supplements for pre-natal, eye, brain and cognitive health; pharmaceutical preparations for neurological, cognitive, behavioral, reproductive, mental and eye health; dietary and nutritional supplements for pre-natal, eye, brain and cognitive health; dietetic beverages for humans for neurological, cognitive, behavioral, reproductive, mental and eye health; dietetic foods for humans adapted for neurological, cognitive, behavioral, reproductive, mental and eye health; dietetic substances for humans adapted for neurological, cognitive, behavioral, reproductive, mental and eye health; cardiovascular pharmaceuticals; pharmaceutical preparations for treating neurological, cognitive, behavioral, reproductive, mental and eye disorders; eye drops; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; food for babies; infant formula; nasal sprays for medical purposes; decongestant nasal sprays; nasal spray preparations
(3) Edible oils.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
Fatty acids for industrial purposes; lecithin for industrial purposes Nutritional supplements; pharmaceuticals being pharmaceutical preparations for treating neurological disorders and eye disorders; dietary and nutritional supplements; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; dietetic substances, namely, dietetic preparations, dietetic foods and beverages, and dietetic infusions adapted for medical use; cardiovascular pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations for eye disorders and neurological disorders; eye drops; ophthalmic preparations; pharmaceutical preparations for the treatment of eye diseases and conditions; food for babies; infant formula; nasal sprays for medical purposes; decongestant nasal sprays; nasal spray preparations Edible oils
The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 9/00 - Medicinal preparations characterised by special physical form
A23K 20/179 - Colouring agents, e.g. pigmenting or dyeing agents
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
C11B 3/16 - Refining fats or fatty oils by mechanical means
The present invention relates to pharmaceutical formulations of phospholipids, and in particular pharmaceutical formulations which are administered intravascularly such as intravenously. In particular, the present invention provides pharmaceutical compositions for intravascular administration comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
The invention provides improved processes for extracting and preparing polar lipids (in particular, desirable phospholipids) from krill and other biological sources. The inventors have discovered processes through which it is possible to extract phospholipids to give high phospholipid content and a reduction of undesired components.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
The present invention provides marine lysophosphatidylcholine compositions for use in pharmaceuticals, nutraceuticals and functional foods, as well as methods for making marine lysophosphatidylcholine compositions.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A23D 9/00 - Other edible oils or fats, e.g. shortenings or cooking oils
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
The present invention provides marine lysophosphatidylcholine (LPC) compositions for use in pharmaceuticals, nutraceuticals and functional foods, as well as methods for making marine lysophosphatidylcholine compositions. Marine LPC compositions are for example provided that include from 10% to 100% LPC w/w, and an omega-3 fatty acid content of from 5% to 50% w/w, wherein the omega-3 fatty acids are linked by ester or ether bonds to phospholipid and glycerol molecules in the composition, and further having a ratio of EPA:DHA of from 1:1 to 3:1 or a ratio of DHA:EPA of from 1:1 to 5:1.
Described herein are at least compounds and formulations that can be or contain a docosahexaenoic acid-lysophosphatidylcholine (DHA-LPC) and/or eicosapenteanoic acid-lysophosphatidylcholine (EPA-LPC). Also described herein are at least methods of making and using the compositions and formulations DHA-LPC and/or EPA-LPC.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
57.
Capsules containing high doses of krill phospholipids
Oral capsules have been dismissed as a dosage form for delivery high dosages of krill phospholipids, but by purifying these to high levels it is indeed possible to use this dosage form to deliver, for example, 700 mg or more phospholipids per capsule.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
Current krill oil extracts are liquid at room temperature and include only about 45-55% phospholipids. As the purity of phospholipids increases, the extracts become more viscous, making them difficult to handle and process. The invention mixes these pure materials with viscosity-reducing agents to make them amenable to processes such as encapsulation. Thus the invention retains the useful liquid characteristics of known krill extracts while providing much higher concentrations of phospholipids.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
Disclosed is a chromatographic process complex for the refining of krill oil extract including desalting, removal of impurities such as trimethylamine oxide (TMAO), and the production of krill oil products including desalted krill oil extract, polar lipid products having polar lipid contents greater than 50 wt-% on a dry or solvent free basis, neutral lipid streams for biodiesel production and astaxanthin. The refinery includes a continuous desalting zone, a fixed bed polar lipid extraction zone to adsorb neutral lipids and astaxanthin to provide a polar lipid extract stream comprising solvent and polar lipids and being essentially free of neutral lipids and astaxanthin, and an astaxanthin separation zone to recover essentially pure astaxanthin and provide a neutral lipid stream. The enriched products of the krill oil refinery are essentially free of TMAO and salt and provide products which can be used as dietary supplements and as medicinal additives.
C07C 45/00 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds
C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
Disclosed is a chromatographic process complex for the refining of krill oil extract including desalting, removal of impurities such as trimethylamine oxide (TMAO), and the production of krill oil products including desalted krill oil extract, polar lipid products having polar lipid contents greater than 50 wt-% on a dry or solvent free basis, neutral lipid streams for biodiesel production and astaxanthin. The refinery includes a continuous desalting zone, a fixed bed polar lipid extraction zone to adsorb neutral lipids and astaxanthin to provide a polar lipid extract stream comprising solvent and polar lipids and being essentially free of neutral lipids and astaxanthin, and an astaxanthin separation zone to recover essentially pure astaxanthin and provide a neutral lipid stream. The enriched products of the krill oil refinery are essentially free of TMAO and salt and provide products which can be used as dietary supplements and as medicinal additives.
C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
C11B 3/10 - Refining fats or fatty oils by adsorption
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A23D 9/013 - Other fatty acid esters, e.g. phosphatides
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The invention provides improved processes for extracting and preparing polar lipids (in particular, desirable phospholipids) from krill and other biological sources. The inventors have discovered processes through which it is possible to extract phospholipids to give high phospholipid content and a reduction of undesired components.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
2 in combination with approximately 20% ethanol. The krill oil materials obtained are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti-inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A23J 7/00 - Phosphatide compositions for foodstuffs, e.g. lecithin
C11B 1/10 - Production of fats or fatty oils from raw materials by extracting
A23L 33/115 - Fatty acids or derivatives thereofFats or oils
A23K 10/20 - Animal feeding-stuffs from material of animal origin
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
C11B 3/16 - Refining fats or fatty oils by mechanical means
A23K 20/179 - Colouring agents, e.g. pigmenting or dyeing agents
A23K 20/158 - Fatty acidsFatsProducts containing oils or fats
The present invention relates to enhanced omega-3 formulations, and in particular to formulations comprising a phospholipid fraction and a triglyceride fraction in combinations with agents that provide a formulation with improved viscosity and dispersion characteristics.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
68.
Method of reducing appetite in a human subject comprising administering krill oil composition
This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. Further, a method of reducing appetite in humans by administering a krill oil composition is also disclosed.
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
The invention provides improved processes for extracting and preparing polar lipids (in particular, desirable phospholipids) from krill and other biological sources. The inventors have discovered processes through which it is possible to extract phospholipids to give high phospholipid content and a reduction of undesired components.
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 35/612 - Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfishBarnacles
The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.
The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
A61K 31/683 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 31/23 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary and nutritional supplements containing oil and
extracts from marine organisms; dietary and nutritional
supplements containing ingredients made in significant part
of krill; dietary supplements for human consumption
containing krill oil or other krill derivatives; food
supplements containing krill; preparations containing
dietary supplements, nutritional additives and dietetic
substances adapted for medical use; functional foods,
namely, nutritional additives for use as ingredients in
foods and dietary supplements for human consumption.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary and nutritional supplements containing oil and
extracts from marine organisms; dietary and nutritional
supplements containing ingredients made in significant part
of krill; dietary supplements for human consumption
containing krill oil or other krill derivatives; food
supplements containing krill; preparations containing
dietary supplements, nutritional additives and dietetic
substances adapted for medical use; functional foods,
namely, nutritional additives for use as ingredients in
foods and dietary supplements for human consumption.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietary and nutritional supplements containing oil and extracts from marine organisms; dietary and nutritional supplements containing ingredients made in significant part of krill; dietary supplements for human consumption containing krill oil or other krill derivatives; food supplements containing krill; nutritional additives for use as ingredients in foods and dietary supplements for human consumption, namely, oil and food extracts derived from marine organisms
01 - Chemical and biological materials for industrial, scientific and agricultural use
04 - Industrial oils and greases; lubricants; fuels
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Oils and extracts from marine organisms, namely, krill and fish, used as ingredients in dietary and nutritional supplements and functional food products; dietary and nutritional supplements containing oils and extracts from marine organisms, namely, krill and fish; dietary and nutritional supplements containing ingredients made significantly of krill; dietary supplements for human consumption containing krill oil or other krill derivatives; food supplements containing krill; preparations containing dietary supplements, nutritional additives and dietetic substances, all for general health and well-being; functional foods, namely, nutritional additives for general health and well-being, for use as ingredients in foods and dietary supplements for general health and well-being.
01 - Chemical and biological materials for industrial, scientific and agricultural use
04 - Industrial oils and greases; lubricants; fuels
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Oils and extracts from marine organisms, namely, krill and fish, used as ingredients in dietary and nutritional supplements and functional food products; dietary and nutritional supplements containing oils and extracts from marine organisms, namely, krill and fish; dietary and nutritional supplements containing ingredients made significantly of krill; dietary supplements for human consumption containing krill oil or other krill derivatives; food supplements containing krill; preparations containing dietary supplements, nutritional additives and dietetic substances, all for general health and well-being; functional foods, namely, nutritional additives for general health and well-being, for use as ingredients in foods and dietary supplements for general health and well-being.
The invention relates to concentrated therapeutic phospholipid compositions; methods for treating or preventing diseases associated with cardiovascular disease, metabolic syndrome, inflammation and diseases associated therewith, neurodevelopmental diseases, and neurodegenerative diseases, comprising administering an effective amount of a concentrated therapeutic phospholipid composition.
This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondrial respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
Nutritional and dietary supplements; medicated additives for food; dietary supplements other than for medical use in the form of edible fats and edible oils. Food additives in the form of edible oils and fats.
This invention discloses new krill oil compositions characterized by having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents. The krill oils are obtained from krill meal using supercritical fluid extraction in a two stage process. Stage 1 removes the neutral lipid by extracting with neat supercritical CO2 or CO2 plus approximately 5% of a co-solvent. Stage 2 extract the actual krill oils by using supercritical CO2 in combination with approximately 20% ethanol. The krill oil materials obatined are compared with commercially available krill oil and found to be more bioeffective in a number of areas such as anti- inflammation, anti-oxidant effects, improving insulin resistances and improving blood lipid profile.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
(1) Nutritional supplements, namely, omega-3 fatty acids or their derivatives in the form of soft gel capsules, capsules with hard shell; dietary supplements and food supplements, namely, omega-3 fatty acids.
(2) Edible oils and fats.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
30 - Basic staples, tea, coffee, baked goods and confectionery
32 - Beers; non-alcoholic beverages
Goods & Services
Soaps; perfumery, essential oils, cosmetics, hair lotions; dentifrices. Pharmaceutical and veterinary preparations; dietetic supplement, nutritional additives and dietetic substances for medical and non-medical use in the form of nutritional bars, meal replacement bars, meal replacement drink mix, health shakes, ready-to-drink mix, minerals, vitamins, mineral substances, trace elements, herbal and plant extracts, energy bars, energy drinks, juice drinks, soft gels, soft gels capsules, capsules with hard shell, tablets, bars, pulverized drink mix, dietetic supplements and food supplements for medical and non-medical use containing fatty acids or fatty acids derivatives, vitamin preparations, diet supplements or nutritional supplements for non-medical use, especially diet supplements or nutritional supplements for non-medical use containing fatty acids or fatty acids derivatives. Meat, fish (not alive), poultry (not alive) and game (not alive); meat extracts; preserved, dried and cooked fruits and vegetables; jellies, jams, compotes; eggs, milk and milk products namely mix containing fat for slices of bread, butter, butter cream, milk drinks (milk predominating), yoghurt, chocolate nut butter, cheese, casein for food, kefir, coconut butter; coconut fat, whey, cream, whipped cream, soybeans, soy milk, tofu, cream cheese, cheese curds, butter milk, sour milk, sour cream; edible oils and fats. Coffee, tea, cocoa, sugar, rice, tapioca, sago, artificial coffee; flour and preparations made from cereals, namely, buns, bread, rolls, cakes, cereal products, biscuits, noodles, fish sauces, pickles, sauces, cereal based snacks, ready-to-eat food bars of cereal food, breakfast cereal mix, pastry and confectionery, ices; honey, treacle; yeast, baking-powder; salt, mustard; vinegar, sauces (condiments); ice, with the exception of spices, spice preparations, flavouring and/or taste improving additives for use in aliments or stimulants, spice mix and/or spice preparations and/or with flavouring and/or taste improving additives for use in aliments or stimulants. Beers; mineral and aerated waters; whey drinks, lemon drinks, selters, vegetable juices, tomato juices, fruit juices, non-alcoholic fruit extracts, unfermented grape paste, isotonic drinks, almond milk, ginger beer; lemon drink preparations, fruit juice preparations, mineral water preparations, carbonated water preparations, drink concentrate, essence for non-alcoholic drink preparations; non alcoholic carbonated and non-carbonated fruit drinks.
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
(1) Nutritional supplements, namely, omega-3 fatty acids or their derivatives in the form of soft gel capsules, dietary supplements and food supplements, namely, omega-3 fatty acids.
(2) Edible oils and fats.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Natural products, namely krill oil for use in the manufacture of nutraceutical, pharmaceutical, bio-pharmaceutical, nutrigenomics, cosmetic and cosmeceutical products.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Natural products, namely krill oil for use in the manufacture of nutraceutical, pharmaceutical, bio-pharmaceutical, nutrigenomics, cosmetic and cosmeceutical products.
